222 related articles for article (PubMed ID: 29127755)
1. [Metabolic syndrome and the role of the polypill in the prevention of its complications].
Rosolová H
Vnitr Lek; 2017; 63(10):712-716. PubMed ID: 29127755
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach.
Santilli F; D'Ardes D; Guagnano MT; Davi G
Curr Med Chem; 2017; 24(24):2602-2627. PubMed ID: 28699503
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment of metabolic syndrome.
Altabas V
Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
[TBL] [Abstract][Full Text] [Related]
4. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
5. Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2014; 20(31):5025-38. PubMed ID: 24320031
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for the metabolic syndrome.
Swislocki AL; Siegel D; Jialal I
Curr Vasc Pharmacol; 2012 Mar; 10(2):187-205. PubMed ID: 22022773
[TBL] [Abstract][Full Text] [Related]
7. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive management of cardiometabolic risk factors.
Early J
Clin Cornerstone; 2007; 8(3):69-80. PubMed ID: 18452843
[TBL] [Abstract][Full Text] [Related]
9. Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill.
Lafeber M; Spiering W; Visseren FL; Grobbee DE
Curr Hypertens Rep; 2016 Apr; 18(5):40. PubMed ID: 27083928
[TBL] [Abstract][Full Text] [Related]
10. Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):146-8. PubMed ID: 17679828
[TBL] [Abstract][Full Text] [Related]
11. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
12. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.
D'Avola D; Cuervas-Mons V; Martí J; Ortiz de Urbina J; Lladó L; Jimenez C; Otero E; Suarez F; Rodrigo JM; Gómez MA; Fraga E; Lopez P; Serrano MT; Rios A; Fábrega E; Herrero JI
Liver Transpl; 2017 Apr; 23(4):498-509. PubMed ID: 28160394
[TBL] [Abstract][Full Text] [Related]
14. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.
Srikanth S; Deedwania P
Curr Hypertens Rep; 2016 Oct; 18(10):76. PubMed ID: 27730495
[TBL] [Abstract][Full Text] [Related]
15. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome revisited: "cardiometabolic risk" emerges as common ground between differing views of the ADA and AHA.
Stern N; Izkhakov Y
J Cardiometab Syndr; 2006; 1(5):362-3. PubMed ID: 17679794
[No Abstract] [Full Text] [Related]
18. Polypill and global cardiovascular health strategies.
Sanz G; Fuster V
Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological management of metabolic syndrome.
Rask Larsen J; Dima L; Correll CU; Manu P
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):397-410. PubMed ID: 29345505
[TBL] [Abstract][Full Text] [Related]
20. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
Greenberg AS
J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
